"We tried to land on Mars and we got to the moon," Novavax Inc. President of R&D Gregory Glenn told BioWorld, referring to the Gaithersburg, Md.-based firm's phase III trial with the respiratory syncytial virus (RSV) vaccine called Resvax. And it was more than anyone had done thus far, he added.

BOGOTA, Colombia – Argentina, hit by a challenging economic crisis, is struggling to supply vaccines to its population. The most recent shortages affect Menveo, a vaccine produced by Glaxosmithkline plc for preventing meningococcal disease.

DUBLIN – Early stage vaccine developer Osivax SAS raised €8 million (U$9 million) in series A funding to continue development of a clinical-stage universal influenza vaccine, based on what it believes is a highly immunogenic method of presenting the viral nucleoprotein to the immune system.